scholarly journals Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study

2019 ◽  
Vol 94 (7) ◽  
pp. 794-802 ◽  
Author(s):  
Noa Biran ◽  
David Siegel ◽  
Jesus G. Berdeja ◽  
Noopur Raje ◽  
Robert Frank Cornell ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Refractory Multiple Myeloma ◽  
Phase 1B

scholarly journals Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

2021 ◽  
Vol 27 (3) ◽  
pp. S387-S388
Author(s):  
Adam D. Cohen ◽  
Parameswaran Hari ◽  
Myo Htut ◽  
Jesus G. Berdeja ◽  
Deepu Madduri ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Patient Expectations ◽  
Refractory Multiple Myeloma ◽  
Phase 1B

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

2016 ◽  
Vol 17 (11) ◽  
pp. 1569-1578 ◽  
Author(s):  
Andrew J Yee ◽  
William I Bensinger ◽  
Jeffrey G Supko ◽  
Peter M Voorhees ◽  
Jesus G Berdeja ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Multicentre Phase ◽  
Refractory Multiple Myeloma ◽  
Phase 1B

A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS8072-TPS8072 ◽  
Author(s):  
David Samuel DiCapua Siegel ◽  
Niels van de Donk ◽  
Pieter Sonneveld ◽  
Craig C. Hofmeister ◽  
Nizar J. Bahlis ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Refractory Multiple Myeloma ◽  
Phase 1B

scholarly journals Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

Haematologica ◽  
2020 ◽  
pp. haematol.2019.243790 ◽  
Author(s):  
Jesus San-Miguel ◽  
Saad Z. Usmani ◽  
Maria-Victoria Mateos ◽  
Niels W.C.J. van de Donk ◽  
Jonathan L. Kaufman ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Dose Escalation ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 1B

scholarly journals Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Blood ◽  
2019 ◽  
Vol 134 (5) ◽  
pp. 421-431 ◽  
Author(s):  
Ajai Chari ◽  
Joaquín Martinez-Lopez ◽  
María-Victoria Mateos ◽  
Joan Bladé ◽  
Lotfi Benboubker ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Options ◽  
Progression Free Survival ◽  
Free Survival ◽  
Refractory Multiple Myeloma ◽  
Common Grade ◽  
Frontline Treatment ◽  
Phase 1B ◽  
Immunomodulatory Drug ◽  
Grade 3

Abstract Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy for frontline treatment of multiple myeloma has resulted in a need for effective regimens for lenalidomide-refractory patients. This phase 1b study evaluated daratumumab plus carfilzomib and dexamethasone (D-Kd) in patients with RRMM after 1 to 3 prior lines of therapy, including bortezomib and an immunomodulatory drug; lenalidomide-refractory patients were eligible. Carfilzomib- and daratumumab-naïve patients (n = 85) received carfilzomib weekly on days 1, 8, and 15 of each 28-day cycle (20 mg/m2 initial dose, escalated to 70 mg/m2 thereafter) and dexamethasone (40 mg/wk). Of these, 10 patients received the first daratumumab dose as a single infusion (16 mg/kg, day 1 cycle 1), and 75 patients received a split first dose (8 mg/kg, days 1-2 cycle 1). Subsequent dosing was per the approved schedule for daratumumab. Patients received a median of 2 (range, 1-4) prior lines of therapy; 60% were lenalidomide refractory. The most common grade 3/4 treatment-emergent adverse events were thrombocytopenia (31%), lymphopenia (24%), anemia (21%), and neutropenia (21%). Infusion-related reactions were observed in 60% and 43% of single and split first-dose patients, respectively. Overall response rate was 84% (79% in lenalidomide-refractory patients). Median progression-free survival (PFS) was not reached; 12-month PFS rates were 74% for all treated patients and 65% for lenalidomide-refractory patients. D-Kd was well tolerated with low neutropenia rates, and it demonstrated deep responses and encouraging PFS, including in patients refractory to lenalidomide. The trial was registered at www.clinicaltrials.gov as #NCT01998971.

Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 8013-8013 ◽  
Author(s):  
Ajai Chari ◽  
Saad Zafar Usmani ◽  
Maria-Victoria Mateos ◽  
Niels Van De Donk ◽  
Jonathan L. Kaufman ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Dose Escalation ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 1B
Sign in / Sign up

Export Citation Format

Share Document